Vemurafenib Patent Expiration
Vemurafenib is Used for treating patients with unresectable or metastatic melanoma with BRAFV600E mutation. It was first introduced by Hoffmann La Roche Inc
Vemurafenib Patents
Given below is the list of patents protecting Vemurafenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Zelboraf | US9447089 | Compositions and uses thereof | Jun 06, 2032 | Hoffmann La Roche |
| Zelboraf | US8741920 | Process for the manufacture of pharmaceutically active compounds | Jul 27, 2030 | Hoffmann La Roche |
| Zelboraf | US7863288 | NA | Jun 20, 2029 | Hoffmann La Roche |
| Zelboraf | US7504509 | Compounds and methods for development of Ret modulators | Oct 22, 2026 | Hoffmann La Roche |
| Zelboraf | US8470818 | NA |
Aug 02, 2026
(Expired) | Hoffmann La Roche |
| Zelboraf | US8143271 | NA |
Jun 21, 2026
(Expired) | Hoffmann La Roche |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Vemurafenib's patents.
Latest Legal Activities on Vemurafenib's Patents
Given below is the list recent legal activities going on the following patents of Vemurafenib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 20 Nov, 2025 | US8741920 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Dec, 2024 | US8470818 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Mar, 2024 | US9447089 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Sep, 2023 | US8143271 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 05 Jul, 2022 | US7863288 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 11 Nov, 2021 | US8741920 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Dec, 2020 | US8470818 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Sep, 2020 | US7504509 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Mar, 2020 | US9447089 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Sep, 2019 | US8143271 |
Vemurafenib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vemurafenib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
